Novo Nordisk's Buyback Blitz Runs Alongside a Parent's Billion-Dollar Exit
Published on 07/06/2026 at 17:13 | Redaktion boerse-global.de
The Danish pharma heavyweight is keeping its share repurchase engine running at full throttle — and the timing looks anything but random. Novo Nordisk has snapped up another 2.42 billion Danish kroner worth of its own B-shares over the past five trading days, even as the stock pulled back 1.15% on Monday to €43.00 after closing at €43.50 on Friday. The intraweek dip does little to dent a rally that has already added more than 15% over the past 30 days, pushing the 14-day Relative Strength Index to 67 — a level that flashes an amber warning for overbought conditions.
The buyback forms part of a larger 15 billion kroner program launched in February 2026 and set to run for 12 months. A sub-tranche targeting B-shares worth up to 11.2 billion kroner kicked off on May 6. Between June 29 and July 3, Novo Nordisk bought 200,000 shares each day at average prices ranging from 314.24 to 326.71 kroner, adding up to 8.25 million shares and the 2.42 billion kroner total. The mandate runs until February 1, 2027, leaving plenty of firepower to deploy the remaining balance. The steady repurchases come as the stock remains roughly 30% below its 52-week high of €61.20 from July 2025, although it has staged a sharp recovery from the March 2026 trough of €30.25. On a 12-month view, the shares are still down about 27%.
Beyond the buyback mechanics, two structural catalysts are reshaping the outlook. The Medicare Bridge Program — which launched in July — allows millions of older U.S. patients to access Novo Nordisk's weight-management drug Wegovy for roughly $50 per month, with the program running through the end of 2027. While rival Eli Lilly enjoys identical pricing terms, thereby neutralizing any direct cost advantage, the expanded addressable market is expected to generate billions in additional revenue. Market observers view this as a durable volume driver rather than a short-term blip, aligning with Novo Nordisk's parallel push to scale up manufacturing capacity for its growing metabolic therapy portfolio.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Separately, Novo Holdings — the controlling shareholder of Novo Nordisk — is cashing in on a portfolio bet. The parent company has agreed to sell its stake in the biotech startup Myricx Bio to Novartis in a deal worth up to $1.5 billion, with $1.1 billion coming as an upfront cash payment. The exit underscores the group's ability to incubate and monetize early-stage platforms, and it comes at a time when the Novo Nordisk stock itself is enjoying a renewed wave of investor enthusiasm. The shares have climbed roughly 20% in recent weeks, closing at 326.90 kroner in Copenhagen and decisively breaking above the 200-day moving average.
Investors now have two key dates circled on the calendar: the second-quarter earnings release on August 5, followed by the capital markets day on September 21, where management is expected to unveil updated financial targets. With the buyback still active, a newly opened Medicare channel, and a parent-level windfall in the pipeline, Novo Nordisk is presenting a picture of multiple tailwinds — even if the share price still has a long way to climb back to its old highs.
Ad
Novo Nordisk Stock: New Analysis - 6 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
